Ramya Vejella, MD
Nephrology · Mesa, AZNPI 1467779413
Payments from drug & device makers
Across 67 payments — averaging $15.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$349
- AstraZeneca$194
- Novartis$131
- Otsuka America Pharmaceutical, Inc.$94
- Boehringer Ingelheim$56
- Bayer$42
- plus $185 from 9 others
What the payments were for
- Food & beverage$1,03298%
- Education$192%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 23 | $349 |
| AstraZeneca | 12 | $194 |
| Novartis | 8 | $131 |
| Otsuka America Pharmaceutical, Inc. | 5 | $94 |
| Boehringer Ingelheim | 3 | $56 |
| Bayer | 2 | $42 |
| Daiichi Sankyo Inc. | 2 | $32 |
| Travere Therapeutics, Inc. | 5 | $27 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $25 |
| Gilead | 1 | $23 |
| Calliditas Therapeutics US Inc. | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Boston Scientific | 1 | $15 |
| Strongbridge US Inc. | 1 | $14 |
| OPKO Pharmaceuticals, LLC | 1 | $12 |
How this compares
$1,051 in reported general payments places this provider in the 30th percentile of 259 nephrology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Allopurinol | 389 | $3,043 |
| Calcitriol | 119 | $2,053 |
| Tacrolimus | 17 | $756 |
| Hydralazine Hcl | 68 | $692 |
| Lisinopril | 84 | $690 |
| Tamsulosin Hcl | 42 | $602 |
| Bumetanide | 17 | $497 |
| Furosemide | 91 | $493 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $447 |
| Amlodipine Besylate | 99 | $415 |
| Fluconazole | 22 | $381 |
| Losartan Potassium | 46 | $356 |
| Potassium Chloride | 36 | $286 |
| Nifedipine ErNifedipine | 12 | $270 |
| Vitamin D2Ergocalciferol (Vitamin D2) | 13 | $263 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Mesa
- Kenneth BorenMesa$1.6M
- Mandeep SahaniMesa$945K
- Asad ChaudharyMesa$6K
- Peter SantosGlendale$3.6M
- Minesh RajpalPeoria$3.6M
- Leslie ThomasPhoenix$3.1M
- Hasan KhamashPhoenix$1.3M
- Roxana NeyraPhoenix$1M
- Randy CooperPeoria$837K
- Amit FadiaTucson$396K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.